Study of CC-93269, a BCMA x CD3 T Cell Engaging Antibody, in Participants With Relapsed and Refractory Multiple Myeloma
Summary
Third Opinion Trial Synopsis:
Study CC-93269-MM-001 is a medical test with people who have a certain type of cancer called multiple myeloma. The test will see if a drug called CC-93269 can help them. The test is divided into four parts and involves trying different amounts of the drug.
Study CC-93269-MM-001 is a medical test with people who have a certain type of cancer called multiple myeloma. The test will see if a drug called CC-93269 can help them. The test is divided into four parts and involves trying different amounts of the drug.
*Third Opinion AI Generated Synopsis
Trial Summary
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
Study CC-93269-MM-001 is an open-label, Phase 1, dose escalation (Part A and C) and expansion (Parts B and D), first-in-human clinical study of CC-93269 in subjects with relapsed and refractory multiple myeloma.
Locations & Contact
Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.
Contacts: